Saturday 17 October 2026
Export ACRV’s income statement to Excel — free account
Acrivon Therapeutics, Inc.
ACRV Healthcare Biotechnology
In the quarter to June 2026, EPS grew 21.8% and free cash flow grew 12.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.64
0.12
−6.82%
Follow ACRV
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(50.23%) | (53.86%) | (60.39%) | (64.63%) | |
| (45.42%) | (47.75%) | (54.38%) | (57.61%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(67.75%) | (71.04%) | (83.24%) | (88.05%) | |
Free Cash Flow per Share |
(1.77) | (1.70) | (1.71) | (1.53) | |
Free Cash Flow |
(68.06) | (65.33) | (66.29) | (64.14) | |
Capital Expenditures |
(2.28) | (1.67) | (1.62) | (1.22) | |
| Other line items | |||||
Cash ROIC |
(26.40%) | (28.27%) | (34.30%) | (36.31%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.80 | 0.82 | 0.84 | 0.85 | |
Depreciation/Fixed assets |
(0.03) | 0.19 | 0.33 | 0.43 | |
Capex/Depreciation |
13.72 | (1.82) | (1.07) | (0.67) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.71) | (1.65) | (1.67) | (1.50) | |
Capex per Share |
(0.06) | (0.04) | (0.04) | (0.03) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates